论文部分内容阅读
早在1968年William首先发现甲状腺髓样癌瘤组织和血浆中PGF含量增加。而后相继报导人类各种肿瘤组织中PGE、PGF量增加。但有关女性生殖道恶性肿瘤患者血浆中PG值的变化在英文文献中尚无报导。本文研究表明女性生殖道恶性肿瘤患者血浆中PGF值较正常对照组为高,且与病情有关,故临床上可作为预后标志。本研究对象共65例,其中肿瘤组24例,对照组41例。肿瘤组中卵巢癌10例、子宫内膜腺癌6例、宫颈鳞状上皮细胞癌5例、子宫混合性苗勒氏瘤2例和外阴癌1例。对照组系18～41岁的健康妇女。确诊后抽血用放射免疫法测定PGF。结果肿瘤组血浆PGF值为25～134pg/ml,均较对照组(21±3.4pg/ml)高,其中卵巢癌、子宫内膜腺癌和宫颈鳞癌患者PGF值与对照组相比有显著差异
As early as 1968, William first found an increase in PGF levels in thyroid medullary carcinoma tissue and plasma. And then have reported a variety of human tumor tissue PGE, PGF increased. However, there is no report in English literature on the changes of plasma PG in female patients with genital tract cancer. This study shows that female patients with reproductive tract cancer PGF plasma levels higher than the normal control group, and with the disease, it can be clinically used as a prognostic marker. A total of 65 subjects in this study, including 24 patients in the tumor group and 41 in the control group. In the tumor group, 10 cases of ovarian cancer, 6 cases of endometrial adenocarcinoma, 5 cases of cervical squamous cell carcinoma, 2 cases of mixed Müller’s tumor and 1 case of vulvar cancer. Control group of 18 to 41-year-old healthy women. Blood samples were taken for determination of PGF by radioimmunoassay after diagnosis. Results The PGF value in the tumor group was 25 ~ 134pg / ml, which was significantly higher than that in the control group (21 ± 3.4pg / ml). The PGF in ovarian cancer, endometrial adenocarcinoma and cervical squamous cell carcinoma were significantly higher than those in the control group difference